M
Min Li
Researcher at City of Hope National Medical Center
Publications - 21
Citations - 893
Min Li is an academic researcher from City of Hope National Medical Center. The author has contributed to research in topics: Progenitor cell & CD34. The author has an hindex of 9, co-authored 14 publications receiving 788 citations. Previous affiliations of Min Li include Beckman Research Institute.
Papers
More filters
Journal ArticleDOI
Effective Targeting of Quiescent Chronic Myelogenous Leukemia Stem Cells by Histone Deacetylase Inhibitors in Combination with Imatinib Mesylate
Bin Zhang,Adam C. Strauss,Su Chu,Min Li,YinWei Ho,Keh-Dong Shiang,David S. Snyder,Claudia S. Huettner,Leonard D. Shultz,Tessa L. Holyoake,Ravi Bhatia +10 more
TL;DR: HDRACi treatment represents an effective strategy to target LSCs in CML patients receiving tyrosine kinase inhibitors and inhibited genes regulating hematopoietic stem cell maintenance and survival.
Journal ArticleDOI
Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt–β-catenin signaling
Bin Zhang,Min Li,Tinisha McDonald,Tessa L. Holyoake,Randall T. Moon,Dario Campana,Leonard D. Shultz,Ravi Bhatia +7 more
TL;DR: It is found that the N-cadherin receptor plays an important role in MSC-mediated protection of CML progenitors from TKI treatment, and increased exogenous Wnt-mediated β-catenin signaling played an important responsibility in protecting CML LSCs in CML patients.
Journal ArticleDOI
MicroRNA-486 regulates normal erythropoiesis and enhances growth and modulates drug response in CML progenitors
Lisheng Wang,Ling Li,Liang Li,Su Chu,Keh-Dong Shiang,Min Li,Hui-Yan Sun,Jun Xu,Feng-Jun Xiao,Guihua Sun,John J. Rossi,YinWei Ho,Ravi Bhatia +12 more
TL;DR: A novel role is revealed in regulating normal hematopoiesis and of BCR-ABL-induced miR-486-5p overexpression in modulating CML progenitor growth, survival, and drug sensitivity.
Journal ArticleDOI
Altered hematopoietic cell gene expression precedes development of therapy-related myelodysplasia/acute myeloid leukemia and identifies patients at risk.
Liang Li,Min Li,Can-Lan Sun,Liton Francisco,Sujata Chakraborty,Melanie Sabado,Tinisha McDonald,Janelle Gyorffy,Karen Chang,Shirong Wang,Wenhong Fan,Jiangning Li,Lue Ping Zhao,Jerald P. Radich,Stephen J. Forman,Smita Bhatia,Ravi Bhatia +16 more
TL;DR: It is concluded that genetic programs associated with t-MDS/AML are perturbed long before disease onset, and accurately identify patients at risk for this complication.
Journal ArticleDOI
Gene expression and mutation-guided synthetic lethality eradicates proliferating and quiescent leukemia cells
Margaret Nieborowska-Skorska,Katherine J. Sullivan,Yashodhara Dasgupta,Paulina Podszywalow-Bartnicka,Grazyna Hoser,Silvia Maifrede,Esteban Martínez,Daniela Di Marcantonio,Elisabeth Bolton-Gillespie,Kimberly Cramer-Morales,Jaewong Lee,Min Li,Artur Slupianek,Daniel Gritsyuk,Sabine Cerny-Reiterer,Ilona Seferynska,Tomasz Stoklosa,Lars Bullinger,Huaqing Zhao,Vera Gorbunova,Katarzyna Piwocka,Peter Valent,Curt I. Civin,Markus Müschen,John E. Dick,Jean C.Y. Wang,Smita Bhatia,Ravi Bhatia,Kolja Eppert,Mark D. Minden,Stephen M. Sykes,Tomasz Skorski +31 more
TL;DR: GEMA-guided targeting of PARP1 resulted in dual cellular synthetic lethality in quiescent and proliferating immature leukemia cells, and is thus a potential approach to eradicate leukemia stem and progenitor cells that are responsible for initiation and manifestation of the disease.